You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Claims for Patent: 12,161,640

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,161,640

Title:	Opioid formulations
Abstract:	A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
Inventor(s):	Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
Assignee:	Camurus AB
Application Number:	US18/500,595
Patent Claims:	1. A method of treating opioid addiction in a patient, the method comprising administering to the patient a composition comprising: about 5% by weight of buprenorphine; about 10% by weight of ethanol; about 42% by weight of phosphatidylcholine; and about 42% by weight of glycerol dioleate, wherein the composition is administered once weekly from a pre-filled syringe, and wherein the patient has previously received buprenorphine. 2. The method of claim 1, wherein the patient has previously received sublingual buprenorphine. 3. The method of claim 1, wherein the composition comprises about 3 to about 40 mg of buprenorphine (calculated as a free base). 4. The method of claim 1, wherein the composition, after contact with an aqueous fluid, forms a liquid crystalline phase structure. 5. The method of claim 4, wherein the liquid crystalline phase structure is a non-lamellar crystalline phase structure. 6. The method of claim 1, wherein, at steady state plasma concentrations, a Cmin and Cmax of buprenorphine in the patient is between about 0.4 ng/ml and 10 ng/ml after administration. 7. The method of claim 1, wherein a Cmin and Cmax of buprenorphine in the patient is between about 0.4 ng/ml and 10 ng/ml for at least a week after administration. 8. The method of claim 1, wherein the blood plasma concentration of buprenorphine in the patient is at least 0.2 ng/ml for at least a week after administration. 9. The method of claim 1, wherein the pre-filled syringe comprises a needle having a gauge greater than 20 G. 10. The method of claim 1, wherein the composition comprises: about 5.29% by weight of buprenorphine; about 10% by weight of ethanol; about 42.36% by weight of a phosphatidylcholine; and about 42.36% by weight of glycerol dioleate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.